Sentences with phrase «led by breast cancer»

On one side of the debate was a team led by breast cancer geneticist Mary - Claire King, who discovered the first inherited breast cancer risk gene, BRCA1.

Not exact matches

TEMECULA — Led by reality television show personality Gillian Larson («Survivor: Gabon»), throngs of volunteers and participants are planning the 8th annual Reality Rally, set for May 3rd - 5th 2018 which is 3 days of unique events, lots of fun and conducted completely to benefit Michelle's Place, Breast Cancer Resource Center.

It was estimated that deaths in hospitals by preventable adverse events exceed the amount attributable to the eight leading cause of death in American (CDC, 1999b) and even exceed the number of deaths cause by automobile accidents (43,458), breast cancer (42,297) or AIDS (16,516)(CDC, 1999a).

Support a multi-year effort led by world - class scientists to develop a blood test for earlier detection of breast cancer when survival rates are the highest, known as the EIF Breast Cancer Biomarker Discovery Prbreast cancer when survival rates are the highest, known as the EIF Breast Cancer Biomarker Discovery Prcancer when survival rates are the highest, known as the EIF Breast Cancer Biomarker Discovery PrBreast Cancer Biomarker Discovery PrCancer Biomarker Discovery Project.

Breast Cancer Care, the leading breast cancer support and information charity in the UK, has produced a new report, backed by Age UK, that makes clear recommendations to improve outcomes and experiences for older women with breast cancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatBreast Cancer Care, the leading breast cancer support and information charity in the UK, has produced a new report, backed by Age UK, that makes clear recommendations to improve outcomes and experiences for older women with breast cancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatCancer Care, the leading breast cancer support and information charity in the UK, has produced a new report, backed by Age UK, that makes clear recommendations to improve outcomes and experiences for older women with breast cancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatbreast cancer support and information charity in the UK, has produced a new report, backed by Age UK, that makes clear recommendations to improve outcomes and experiences for older women with breast cancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatcancer support and information charity in the UK, has produced a new report, backed by Age UK, that makes clear recommendations to improve outcomes and experiences for older women with breast cancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatbreast cancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatcancer, a demographic proven to have poorer relative survival rates and an increased likelihood of presenting later with symptoms and of receiving non-standard treatments.

The study, led by Dr Len Stephens and Dr Phill Hawkins and published today in the journal Molecular Cell, reveals why loss of the PTEN gene has such an impact on many people with prostate cancer, as well as in some breast cancers.

The researchers at 30 radiotherapy centres across the UK, led by The Institute of Cancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of comingCancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of comingCancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of comingcancer that was at a low risk of coming back.

Extensive studies have found that 20 % to 30 % of breast cancers are characterized by over-expression of HER2, which makes the cancer cells grow and divide faster, leading to a cancer that's more aggressive and more likely to be resistant to the standard of care.

Breast cancer kills about 40,000 women annually making it the second leading cause of cancer death in women — exceeded only by lung cancer, according to the American Cancer Socancer kills about 40,000 women annually making it the second leading cause of cancer death in women — exceeded only by lung cancer, according to the American Cancer Socancer death in women — exceeded only by lung cancer, according to the American Cancer Socancer, according to the American Cancer SoCancer Society.

Previous work led by Charlotte Kuperwasser, principal investigator, determined that some common forms of breast cancer originate from luminal cells while some rarer forms of breast cancer originate from basal cells.

A team led by Mary - Frances O'Connor of the University of California, Los Angeles, studied 23 women — 11 of whom suffered from CG — who had lost a mother or sister to breast cancer in the past five years.

The three Ras genes found in humans — H - Ras, K - Ras and N - Ras — were among the first to be linked to cancer development, and a new study led by VCU Massey Cancer Center researcher Paul Dent, Ph.D., has shown the recently approved breast cancer drug neratinib can block the function of Ras as well as several other oncogenes through an unexpected prcancer development, and a new study led by VCU Massey Cancer Center researcher Paul Dent, Ph.D., has shown the recently approved breast cancer drug neratinib can block the function of Ras as well as several other oncogenes through an unexpected prCancer Center researcher Paul Dent, Ph.D., has shown the recently approved breast cancer drug neratinib can block the function of Ras as well as several other oncogenes through an unexpected prcancer drug neratinib can block the function of Ras as well as several other oncogenes through an unexpected process.

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Ccancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Ccancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer CCancer Center.

Initial results were announced from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,cancer sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,Cancer Research Group (ECOG - ACRIN) with support from Genomic Health, Inc..

Led by researchers at Boston University School of Medicine (BUSM), the study appears online in Breast Cancer Research.

For the current study, scientists led by Helmneh Sineshaw, M.D., MPH, analyzed data from 260,174 breast cancer cases recorded in the National Cancer Data Base (NCDB), a national hospital - based cancer registry database jointly sponsored by the American College of Surgeons and the American Cancer Socancer cases recorded in the National Cancer Data Base (NCDB), a national hospital - based cancer registry database jointly sponsored by the American College of Surgeons and the American Cancer SoCancer Data Base (NCDB), a national hospital - based cancer registry database jointly sponsored by the American College of Surgeons and the American Cancer Socancer registry database jointly sponsored by the American College of Surgeons and the American Cancer SoCancer Society.

Researchers at the University of Melbourne, led by Professor Melissa Southey, looked at 210 people from 25 multiple - case breast cancer families.

A team of researchers led by UC San Francisco scientists has identified a new drug target for triple - negative breast cancer, an aggressive disease subtype that has the poorest outcomes and accounts for as many as one in five cases.

«It's incredibly encouraging to find possible new options for patients with an aggressive cancer like triple negative breast cancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thcancer like triple negative breast cancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thcancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thCancer Center, and former CEO of the ICR.

The Nature Communications paper covers lung cancer cells; a similar phenomenon of collective invasion led by distinctive cells has been observed in breast cancer, but different genes and biochemical pathways appear to be important in each system.

By manipulating it in vitro, a team of researchers led by Prof. David Mooney at Harvard SEAS have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast canceBy manipulating it in vitro, a team of researchers led by Prof. David Mooney at Harvard SEAS have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast canceby Prof. David Mooney at Harvard SEAS have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast canceby which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast cancer.

«We are excited and gratified by these remarkable results, which could lead to a new way to treat these drug resistant metastases of ER + breast cancers and / or prevent their metastases in the first place.»

The findings could lead to future investigation into potential new ways to treat and monitor breast cancer by looking outside the tumor and exploiting the patient's systemic immune system response.

In the new study, a team led by Vanessa Dumeaux during her time at McGill University examined links between gene expression in breast cancer tumors and in the bloodstream.

An international collaboration, led by the Wellcome Trust Sanger Institute with contributions from the European Bioinformatics Institute (EMBL - EBI), analysed 560 breast cancer genomes from cancer patients from the US, Europe and Asia.

By combining two modalities of imaging, investigators from Norris Cotton Cancer Center at Dartmouth, led by Keith Paulsen, PhD with first author Michael Mastanduno and collaborators from Xijing Hospital in Xian, China, demonstrated that a dual breast exam using MRI and Near Infrared Spectral Tomography (NIRST) is feasible and more accurate than MRI alonBy combining two modalities of imaging, investigators from Norris Cotton Cancer Center at Dartmouth, led by Keith Paulsen, PhD with first author Michael Mastanduno and collaborators from Xijing Hospital in Xian, China, demonstrated that a dual breast exam using MRI and Near Infrared Spectral Tomography (NIRST) is feasible and more accurate than MRI alonby Keith Paulsen, PhD with first author Michael Mastanduno and collaborators from Xijing Hospital in Xian, China, demonstrated that a dual breast exam using MRI and Near Infrared Spectral Tomography (NIRST) is feasible and more accurate than MRI alone.

Their findings could help to improve breast cancer prevention by targeting these specific biological mechanisms with cancer therapies in at risk patients and potentially lead the way for a new strategy for the use of preventative treatments.

Women with higher breast density — detected on mammograms — have more compacted breast tissue and are more likely to develop breast cancer, but until now the reasons for this have been unclear.Manchester scientists, funded by leading UK research organisation Breakthrough Breast Cancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms atbreast density — detected on mammograms — have more compacted breast tissue and are more likely to develop breast cancer, but until now the reasons for this have been unclear.Manchester scientists, funded by leading UK research organisation Breakthrough Breast Cancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms atbreast tissue and are more likely to develop breast cancer, but until now the reasons for this have been unclear.Manchester scientists, funded by leading UK research organisation Breakthrough Breast Cancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms atbreast cancer, but until now the reasons for this have been unclear.Manchester scientists, funded by leading UK research organisation Breakthrough Breast Cancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms atcancer, but until now the reasons for this have been unclear.Manchester scientists, funded by leading UK research organisation Breakthrough Breast Cancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms atBreast Cancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms atCancer, worked with IBM researchers and academics in the USA and Cyprus to uncover the biological mechanisms at play.

Scientists, led by Ottar Rolfssonat the University of Iceland, have built a mathematical model to examine the metabolism of breast epithelium — as the majority of breast cancers originate from these cells.

Therefore, his team, led by postdoctoral fellow Gayatri Arun, set out to discover what would happen if mice that model human metastatic breast cancer were bred with the mice lacking Malat1.

A group led by Eleanor Rogan, a cancer researcher at the University of Nebraska Medical Center in Lincoln, took samples of healthy breast tissue from women with and without cancer and measured the amounts of estrogen derivatives.

«Drug provides another treatment option for an early form of breast cancer: The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London.»

«Considering that Florida ranks second in the number of pancreatic cancer deaths that occur each year and the fact that pancreatic cancer is projected to surpass breast, prostate, and colorectal cancer and become the second leading cause of cancer deaths by 2030, we are thrilled that our state is committed to investing in pancreatic cancer research now,» said Permuth - Wey.

Researchers led by Dr. Debra Auguste, associate professor, biomedical engineering, in the Grove School of Engineering at The City College of New York, have identified a molecule that could lead to developing treatment for one of the most aggressive forms of breast cancer.

Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Ccancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer CCancer Center.

Houston Methodist researchers led by Dario Marchetti, PhD, have developed a blood test that can identify circulating tumor cells to predict breast cancer patients at risk for developing brain metastasis.

Now a research team led by investigators in the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breast cCancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breast cancercancer.

Taking the focus off pain management and specific post-treatment symptoms, and putting it on quality of life defined as «active engagement,» a team from Dartmouth's Norris Cotton Cancer Center, led by Mark T. Hegel, PhD with first - author Kathleen D. Lyons, ScD, established and tested a new paradigm for working with breast cancer survCancer Center, led by Mark T. Hegel, PhD with first - author Kathleen D. Lyons, ScD, established and tested a new paradigm for working with breast cancer survcancer survivors.

In a study presented at the 2016 San Antonio Breast Cancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemothBreast Cancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemothCancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemothbreast cancer patients will respond to chemothcancer patients will respond to chemotherapy.

A Houston Methodist team led by Mauro Ferrari, PhD and Jenny Chang, MD has received funding from the U.S. Department of Defense to complete preclinical efficacy studies and a future clinical trial testing a breast cancer precision drug.

Lead author, Professor Kelly - Anne Phillips says this study, the largest to date, suggests that it could work for these high - risk women by halving their breast cancer risk.

A research team, led by Chao Cheng, Ph.D., Assistant Professor in the Department of Genetics at The Geisel School of Medicine at Dartmouth, used gene expression data from breast cancer patients to computationally infer the presence of different types of immune cells.

In addition, the study, led by investigators in The Cancer Genome Atlas (TCGA) Research Network, revealed four novel tumor subtypes, while also identifying genomic similarities between endometrial and other cancer types, including breast, ovarian, and colorectal caCancer Genome Atlas (TCGA) Research Network, revealed four novel tumor subtypes, while also identifying genomic similarities between endometrial and other cancer types, including breast, ovarian, and colorectal cacancer types, including breast, ovarian, and colorectal cancers.

A study published in PLOS Genetics, led by Kerstin Lindblad - Toh at Uppsala University / SciLifeLab, sheds new light on the genetics behind breast cancer.

By looking at the DNA in your samples, researchers can make discoveries that will ultimately lead to a better understanding and faster advances in the treatment of metastatic breast cancer.

Founded in 1994 by women's health activists, Silent Spring Institute leads groundbreaking studies to identify the links between environmental chemicals and breast cancer, opening new doors to understanding the health risks associated with toxics where we live and work.

Research Director, Silent Spring Institute Website Ruthann Rudel is the research director at Silent Spring Institute, where she leads major exposure and toxicology research programs focusing on hormonally active chemicals and biological mechanisms by which chemicals may influence breast cancer.

In the new study, scientists at King's College London, led by Dr Anita Grigoriadis from the Breast Cancer Now Research Unit at King's College London, studied lymph node tissue and primary tumour samples from 309 breast cancer patients, who were treated between 1984 and 2002 at Guy's Hospital LBreast Cancer Now Research Unit at King's College London, studied lymph node tissue and primary tumour samples from 309 breast cancer patients, who were treated between 1984 and 2002 at Guy's Hospital LCancer Now Research Unit at King's College London, studied lymph node tissue and primary tumour samples from 309 breast cancer patients, who were treated between 1984 and 2002 at Guy's Hospital Lbreast cancer patients, who were treated between 1984 and 2002 at Guy's Hospital Lcancer patients, who were treated between 1984 and 2002 at Guy's Hospital London.

Through its various targets, MMP1 promotes not only tumor invasion but also breast cancer colonization to bone by mechanisms that include the release of membrane - bound EGF - like growth factors from tumor cells, leading to activation of EGF receptor signaling and suppression of OPG expression in osteoblasts, which in turn promotes the differentiation and activation of osteoclasts required for bone destruction and enhanced tumor growth in the bone microenvironment (32).

A CUMC - led study finds that acupuncture can reduce the joint pain caused by aromatase inhibitors, a drug taken by two - thirds of all breast cancer patients.